EU GMP Annex 1 defines how sterile pharmaceutical products must be manufactured, with the goal of minimizing contamination risk and ensuring patient safety. The revised guidance places significantly greater emphasis on contamination prevention by design, requiring manufacturers to demonstrate control not only at the point of filling, but across facilities, processes, and primary packaging throughout the entire product lifecycle.
Practical Solutions for Annex 1 Compliance Across the Sterile Manufacturing Workflow
A central requirement under Annex 1 is a documented Contamination Control Strategy supported by Quality Risk Management. Together, these frameworks require manufacturers to proactively identify contamination risks, reduce manual handling, justify critical design choices, and demonstrate a consistent and controlled state of operation, particularly for aseptically processed and non-terminally sterilized products.
For many manufacturers, especially those operating long established facilities, these expectations create real challenges. Traditional in-house container preparation activities such as washing, depyrogenation, sterilization, and transfer into cleanroom environments are increasingly viewed as avoidable contamination risks rather than value-adding steps. As a result, regulators now place greater emphasis on ready to use primary packaging components that simplify workflows and strengthen sterility assurance.
DWK Life Sciences supports Annex 1 compliance across both upstream and downstream operations. DURAN™ PURE bottles, manufactured from high purity Type I borosilicate glass, provide a robust upstream containment solution for sterile APIs, intermediates, and biologics, offering excellent chemical resistance, very low extractables risk, and reliable container closure performance during storage and transport. By controlling contamination risk earlier in the process, they help prevent variability and risk from being carried into the aseptic core.
DWK Life Sciences adds value through its RTX services, including validated sterilization and cleaning processes, comprehensive documentation and certification, full traceability and change control, and expert technical support aligned with Contamination Control Strategy and Quality Risk Management requirements for DURAN™ PURE containers.
At fill and finish, WHEATON™ CompletePAK and Stevanato Group EZ-fill™ Vials support Annex 1 expectations by reducing handling and enabling engineered sterility control. Supplied prewashed, depyrogenated, and sterilized using validated processes, these vial systems remove high risk in-house preparation steps and enable controlled and repeatable transfer into isolators or restricted access barrier systems (RABS). This simplifies Contamination Control Strategy justification, reduces human intervention, supports stable airflow conditions, and strengthens container closure integrity.
Together, DWK Life Sciences upstream and downstream solutions enable manufacturers to translate Annex 1 requirements into practical and defensible sterility assurance, reducing contamination risk, simplifying compliance, and supporting confident inspection readiness across the full sterile manufacturing lifecycle.
Related Products
Product Code 15390594
Product Code 17972591